Approximately 80% of human bladder cancers (BC) are non-muscle invasive when first diagnosed and are usually treated by transurethral tumor resection. But 50-80% of patients experience cancer recurrence. Agents for prevention of primary BC have yet to be identified. Existing prophylactics against BC recurrence, e.g., Bacillus Calmette-Guerin (BCG), have limited efficacy and utility; they engender significant side effects and require urethral catheterization. Many cruciferous vegetables, rich sources of isothiocyanates (ITCs), are commonly consumed by humans. Many ITCs possess promising chemopreventive activities against BC and its recurrence. Moreover, orally ingested ITCs are selectively delivered to bladder via urinary excretion. This review is focused on urinary delivery of ITCs to the bladder, their cellular uptake, their chemopreventive activities in preclinical and epidemiological studies that are particularly relevant to prevention of BC recurrence and progression, and their chemopreventive mechanisms in BC cells and tissues.
Approximately 80% of humann class="Disease">bladder cancers (BC) are non-muscle invasive when first diagnosed and are usually treated by transurethral tumor resection. But 50-80% of patients experience cancer recurrence. Agents for prevention of primary BC have yet to be identified. Existing prophylactics against BC recurrence, e.g., Bacillus Calmette-Guerin (BCG), have limited efficacy and utility; they engender significant side effects and require urethral catheterization. Many cruciferous vegetables, rich sources of isothiocyanates (ITCs), are commonly consumed by humans. Many ITCs possess promising chemopreventive activities against BC and its recurrence. Moreover, orally ingested ITCs are selectively delivered to bladder via urinary excretion. This review is focused on urinary delivery of ITCs to the bladder, their cellular uptake, their chemopreventive activities in preclinical and epidemiological studies that are particularly relevant to prevention of BC recurrence and progression, and their chemopreventive mechanisms in BC cells and tissues.
Authors: Li Tang; Gary R Zirpoli; Khurshid Guru; Kirsten B Moysich; Yuesheng Zhang; Christine B Ambrosone; Susan E McCann Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-06-15 Impact factor: 4.254
Authors: Hyung Sun Youn; Yoon Sun Kim; Zee Yong Park; So Young Kim; Na Young Choi; Sun Myung Joung; Jung A Seo; Kyung-Min Lim; Mi-Kyoung Kwak; Daniel H Hwang; Joo Young Lee Journal: J Immunol Date: 2009-11-30 Impact factor: 5.422
Authors: Shivendra V Singh; Renaud Warin; Dong Xiao; Anna A Powolny; Silvia D Stan; Julie A Arlotti; Yan Zeng; Eun-Ryeong Hahm; Stanley W Marynowski; Ajay Bommareddy; Dhimant Desai; Shantu Amin; Robert A Parise; Jan H Beumer; William H Chambers Journal: Cancer Res Date: 2009-02-17 Impact factor: 12.701
Authors: Besma Abbaoui; Kelly H Telu; Christopher R Lucas; Jennifer M Thomas-Ahner; Steven J Schwartz; Steven K Clinton; Michael A Freitas; Amir Mortazavi Journal: J Proteomics Date: 2017-01-27 Impact factor: 4.044
Authors: Sarandeep S S Boyanapalli; Wenji Li; Francisco Fuentes; Yue Guo; Christina N Ramirez; Ximena-Parades Gonzalez; Douglas Pung; Ah-Ng Tony Kong Journal: Pharmacol Res Date: 2016-11-03 Impact factor: 7.658
Authors: Besma Abbaoui; Christopher R Lucas; Ken M Riedl; Steven K Clinton; Amir Mortazavi Journal: Mol Nutr Food Res Date: 2018-08-29 Impact factor: 5.914
Authors: Yuxuan Zheng; Jeffrey D Ritzenthaler; Tom J Burke; Javier Otero; Jesse Roman; Walter H Watson Journal: Free Radic Biol Med Date: 2018-02-16 Impact factor: 7.376
Authors: Melanie Wiesner-Reinhold; Monika Schreiner; Susanne Baldermann; Dietmar Schwarz; Franziska S Hanschen; Anna P Kipp; Daryl D Rowan; Kerry L Bentley-Hewitt; Marian J McKenzie Journal: Front Plant Sci Date: 2017-08-03 Impact factor: 5.753